The final stages of pancreatic cancer bring a constellation of physical changes that tend to follow a recognizable, if variable, pattern: escalating pain, progressive weight loss, jaundice, difficulty eating, and a gradual withdrawal from wakefulness. The disease’s aggressiveness is part of what makes the late trajectory so distinct from many other cancers. Research on pancreatic cancer’s genetic evolution suggests patients live an average of about two years after the cancer gains the ability to spread to distant organs, and more than 80 percent of patients already have advanced disease at diagnosis. Understanding what those final weeks and months look like can help families and patients prepare, make informed decisions about comfort care, and recognize the signposts that indicate when the end is near.
How Pancreatic Cancer Spreads in Late Stages
By the time pancreatic cancer reaches its final stages, it has almost always moved beyond the pancreas itself. The liver is the most common destination, but the peritoneum, the membrane lining the abdominal cavity, is the second most frequent site. Up to half of patients who initially had surgery with the hope of a cure eventually develop peritoneal metastasis, which drives much of the suffering in late-stage disease.1PubMed Central. Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma The lungs and bones can also be involved, though less commonly.
Genetic analysis of pancreatic tumors reveals something that helps frame expectations: the mutations enabling distant spread develop years before symptoms appear. At least a decade passes between the first cancer-causing mutation and the formation of a non-metastatic tumor, and roughly five more years pass before the cancer acquires the ability to metastasize.2Nature. Distant metastasis occurs late during the genetic evolution of pancreatic cancer By the time a patient reaches the final stages, the cancer has been silently evolving for many years. This long hidden timeline explains why curative treatment is so difficult and why the late-stage experience is often one of rapid visible decline after a disease that was undetectable for over a decade.
Pain and How It Is Managed
Pain is one of the defining features of advanced pancreatic cancer. Somewhere between half and 70 percent of patients experience severe pain over the course of the disease, and in the final stages it often intensifies as the tumor invades surrounding nerves and organs.3PubMed Central. Celiac plexus block for pancreatic cancer pain in adults The pain typically centers in the upper abdomen and radiates to the back, because the pancreas sits deep in the abdomen right against a major nerve bundle called the celiac plexus.
Standard pain management follows a stepwise approach, starting with over-the-counter medications and moving to opioids as the disease progresses. But pancreatic cancer pain can be stubbornly difficult to control with medications alone. A procedure called a celiac plexus block, in which a doctor injects a chemical to destroy or numb the nerve bundle near the pancreas, is considered a safe and effective option at any stage of the disease. It can reduce the visceral component of pain, the deep ache originating from the organ itself, and allow patients to use lower doses of opioids.4PubMed. Celiac plexus block for pancreatic cancer pain: factors influencing pain, symptoms and quality of life One limitation is that as the tumor grows and distorts the anatomy around the celiac axis, the nerve block becomes harder to perform and less effective. This is a practical reality families should discuss with the palliative care team earlier rather than later.
For patients whose pain becomes truly refractory, meaning it resists all standard approaches, palliative sedation is sometimes considered. In a small case series of terminal cancer patients with unmanageable pain, dexmedetomidine combined with patient-controlled analgesia provided effective sedation while keeping breathing stable.5PubMed Central. Dexmedetomidine Combined With Patient-Controlled Analgesia for Palliative Sedation in Terminal-Stage Cancer Patients With Refractory Pain: A Retrospective Analysis of Nine Cases Palliative sedation is not the same as euthanasia; it reduces consciousness to relieve suffering without intending to hasten death. It is typically reserved for the very end of life when no other option provides comfort.
Jaundice and Difficulty Eating
The pancreas sits at a crossroads of the digestive system, and as the tumor grows it can block two critical passageways: the bile duct and the upper part of the small intestine. Blockage of the bile duct causes obstructive jaundice, which turns the skin and eyes yellow, causes intense itching, darkens urine, and lightens stool color. Blockage of the duodenum, the section of bowel just past the stomach, causes what doctors call gastric outlet obstruction, leading to persistent nausea, vomiting, and an inability to keep food down.6PubMed Central. Palliative therapy in pancreatic cancer-palliative surgery
Both of these complications are common and treatable, even when the cancer itself is not. For jaundice, the standard approach is to place a small metal tube called a stent inside the bile duct during an endoscopic procedure, which reopens the channel and allows bile to drain normally. Endoscopic metal stents are considered the current standard for relieving jaundice in patients with inoperable pancreatic cancer.7PubMed Central. Palliative biliary stents for obstructing pancreatic carcinoma These stents generally control jaundice successfully, though they can malfunction over time and need replacement.8PubMed Central. Palliative Endoscopic Treatment Options in Malignancies of the Biliopancreatic System
For gastric outlet obstruction, the options are either an endoscopic duodenal stent or a surgical bypass that reroutes food around the blockage. The stent approach lets patients return to eating sooner, shortens hospital stays, and allows earlier resumption of chemotherapy.9PubMed. Endoscopic duodenal stent versus surgical gastrojejunostomy for gastric outlet obstruction in patients with advanced pancreatic cancer However, stents tend to need re-intervention more often than surgery does.10PubMed Central. Palliative management for malignant biliary obstruction and gastric outlet obstruction from pancreatic cancer When life expectancy is measured in weeks, the faster recovery of a stent typically makes more sense; when it is measured in months, a surgical bypass may prove more durable.
Severe Weight Loss and Cachexia
Almost everyone with advanced pancreatic cancer loses weight, and in many cases the weight loss is profound and relentless. The medical term for this is cachexia, and it affects roughly 70 to 80 percent of pancreatic cancer patients.11PubMed Central. Pancreatic Cancer and Cachexia-Metabolic Mechanisms and Novel Insights Cachexia is not ordinary malnutrition from not eating enough. It is a systemic metabolic process driven by the tumor itself, which releases substances that accelerate muscle and fat breakdown regardless of caloric intake. Families often feel desperate to get their loved one to eat more, and it can be agonizing to watch someone waste away despite being offered food. But cachexia does not respond to simply eating more; the body’s metabolic machinery has been hijacked by the cancer.
The tumor triggers widespread inflammation and metabolic disruption across multiple organs, including appetite-suppressing effects on the brain, dysfunction in the gut, and even cardiac changes.12hLife. Pancreatic cancer cachexia: A systemic consequence of multi-organ interactions This cascade creates a vicious cycle: the worse the cachexia, the faster the disease progresses. Nutritional support from a dietitian can help maintain comfort and potentially slow the process somewhat, but reversing cachexia in advanced pancreatic cancer remains one of the most stubborn challenges in oncology. Knowing this can relieve some of the guilt that families feel when their loved one stops eating. It is not a failure of care; it is the disease itself.
Ascites and Abdominal Swelling
As the cancer spreads through the peritoneum, fluid often accumulates in the abdomen, a condition called malignant ascites. This buildup causes visible abdominal distension, pressure, pain, breathing difficulty, and reduced mobility. Malignant ascites generally signals the terminal phase of the disease, and its management focuses on symptom relief rather than cure.13PubMed Central. Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies
The most straightforward treatment is paracentesis, a procedure in which a needle drains the excess fluid from the abdomen. Some patients need this done repeatedly, and the fluid tends to re-accumulate within days to weeks. For patients who require frequent drainage, doctors sometimes place a semi-permanent catheter, most commonly a Tenckhoff catheter, that allows fluid to be drained at home or at the bedside without repeated hospital trips. In one study of pancreatic cancer patients with ascites, about a third were managed with serial paracentesis alone, while the majority required a catheter. The main complications included infection (spontaneous bacterial peritonitis) in roughly 11 to 23 percent of cases, and occasional catheter malfunction.14PubMed Central. Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications A semi-permanent drain can substantially improve quality of life by allowing more frequent, smaller-volume drainages without the discomfort and logistics of repeated hospital visits.15PubMed Central. Palliative semi-permanent abdominal drain for the management of refractory malignant ascites
Blood Clots
Pancreatic cancer has one of the highest rates of blood clot formation among all cancers, a connection first observed clinically over 150 years ago. The cancer creates a hypercoagulable state through multiple mechanisms, including the production of mucin (a thick, gel-like substance) and the release of tissue factor, a protein that triggers the clotting cascade.16PubMed Central. Pancreatic cancer and thromboembolic disease, 150 years after Trousseau Research has found that about 70 percent of patients with pancreatic cancer have detectable tissue factor-bearing microparticles in their blood, tiny fragments shed by tumor cells that promote clotting far from the tumor itself.17Blood. Trousseau’s Syndrome Revisited: Tissue Factor-Bearing Microparticles in Pancreatic Cancer
In practical terms, this means that deep vein thrombosis in the legs, pulmonary embolism in the lungs, and other clotting events are a real risk throughout the course of the disease but especially in its final stages, when patients are less mobile and more debilitated. Sometimes an unexpected blood clot is even the event that leads to the cancer diagnosis in the first place. For patients in the final stages, the decision about whether to continue blood-thinning medication involves weighing the burden of injections and bleeding risk against the discomfort and danger of clots. There is no universal right answer; it depends on the patient’s overall condition and goals of care.
Confusion, Delirium, and Withdrawal
In the last weeks of life, many patients with advanced pancreatic cancer experience changes in consciousness. Terminal delirium, a state of fluctuating confusion, agitation, or drowsiness, is extremely common. In one study comparing patients who received a celiac plexus block to those managed with standard pain control alone, terminal delirium occurred in 42 percent of the nerve-block group versus 94 percent of the control group, and when it did appear, it lasted far fewer days.18PubMed. Neurolytic celiac plexus block reduces occurrence and duration of terminal delirium in patients with pancreatic cancer This suggests that better pain control may delay or reduce delirium, though it does not eliminate it entirely.
Delirium can be deeply distressing for families. A person who was coherent yesterday may not recognize loved ones today, or may become agitated, pick at bedsheets, or call out. It helps to know that this is a neurological process driven by the body’s progressive shutdown, not a reflection of emotional distress or unfinished psychological business, though those factors can coexist. Keeping the environment calm, speaking in a soothing voice, and avoiding unnecessary stimulation can help. Medications like haloperidol or benzodiazepines are sometimes used when agitation is severe.
What the Final Days and Hours Look Like
A large prospective study of patients with advanced cancer identified a set of physical signs that reliably appear in the last three days of life. These signs were overwhelmingly neurological in nature, reflecting the progressive shutdown of the brain and nervous system. They included non-reactive pupils, decreased responses to verbal and visual stimulation, inability to close the eyelids, drooping of the nasolabial fold (the crease running from the nose to the corner of the mouth), hyperextension of the neck, and grunting sounds from the vocal cords.19PubMed Central. Bedside clinical signs associated with impending death in patients with advanced cancer: Preliminary findings of a prospective longitudinal cohort study These signs were observed in 38 to 78 percent of patients in their final three days and were highly specific, meaning that when they appeared, death within three days was very likely.
Other widely recognized signs of the final hours include Cheyne-Stokes breathing (a pattern of deep breaths alternating with pauses), jaw movement during breathing, and the “death rattle,” a gurgling sound caused by secretions in the throat. These are all driven by the same progressive neurological decline. They can be distressing to witness, but the patient is typically unaware and not suffering from them. Suctioning the throat is sometimes attempted for the death rattle but is often ineffective; repositioning the patient and using medications to reduce secretion production are more commonly recommended.
Functional decline in the final days is steep. Tools that measure a patient’s ability to perform daily activities, such as the Palliative Performance Scale, show a strong relationship with survival. Patients at the lowest functional levels, essentially bedbound and barely conscious, have median survival measured in just one to three days.20PubMed Central. Using the Palliative Performance Scale to Estimate Survival for Patients at the End of Life: A Systematic Review of the Literature This information, while sobering, can help families understand when death is imminent and make decisions about who needs to be present and what final conversations to have.
Early Palliative Care Makes a Measurable Difference
One of the most important things to understand about the final stages of pancreatic cancer is that palliative care, specialized medical care focused on symptom relief and quality of life, does not have to wait until the very end. In fact, research shows that starting palliative care early alongside cancer treatment can improve quality of life. A study of patients with advanced pancreatic cancer found that those with metastatic disease who received early palliative care showed a meaningful reduction in symptom burden over 16 weeks.21SpringerLink / Support Care Cancer. The impact of early palliative care on the quality of life of patients with advanced pancreatic cancer: The IMPERATIVE case-crossover study
In practice, a palliative care team coordinates pain management, addresses nausea and appetite issues, helps with emotional support, and guides families through difficult decisions about the goals of treatment. This is not the same as hospice, which focuses on comfort care when life expectancy is six months or less. Palliative care can run in parallel with chemotherapy and other active treatments. Asking about palliative care early is one of the most impactful steps a patient or family can take.
Decisions About Nutrition at the End of Life
One of the most emotionally fraught decisions families face is whether to continue artificial nutrition and hydration as the patient declines. When someone can no longer eat or drink, the instinct is to provide IV fluids or tube feeding. But in the terminal phase, artificial nutrition often does not prolong life and can increase discomfort by worsening fluid retention, ascites, and respiratory secretions.
In surveys of physicians and nurses who care for dying patients, the most common ethical reasons for stopping artificial nutrition were the principles of beneficence (acting in the patient’s best interest), non-maleficence (avoiding harm), and patient autonomy.22PubMed Central. The use of artificial nutrition at the end-of-life: a cross-sectional survey exploring the beliefs and decision-making among physicians and nurses In practice, stopping artificial feeding in the final days is not starving the patient. The body in its dying process has already lost the ability to use nutrition effectively. Mouth care, small sips of water if the patient is alert enough, and lip moistening provide comfort without the risks of IV or tube feeding. Having this conversation early, ideally as part of advance care planning, spares families from making the decision under crisis conditions.
The Toll on Caregivers
Pancreatic cancer takes a unique psychological toll on the people providing care. Because the disease moves so fast and the prognosis is so poor, caregivers often experience what researchers describe as preparatory mourning, grieving the loss before it has happened. Qualitative studies have found that caregivers become hypervigilant about symptoms and skeptical of any good news from the medical team, living in a state of persistent foreboding.23PubMed Central. The psychosocial impact of pancreatic cancer on caregivers: a scoping review
The numbers reflect this burden starkly. In systematic reviews of caregiver wellbeing, about 39 percent of caregivers for pancreatic cancer patients had anxiety scores at clinical levels, and roughly 15 percent had clinical-level depression. There was a strong correlation between the patient’s emotional state and the caregiver’s: when the patient was more anxious, the caregiver tended to be as well. Partners of pancreatic cancer patients were also more likely to receive their first prescription for anti-anxiety medication compared to the general population.24PubMed Central. Systematic review of caregiver burden, unmet needs and quality-of-life among informal caregivers of patients with pancreatic cancer
If you are caring for someone with advanced pancreatic cancer, these statistics are not meant to alarm you but to validate what you may already be feeling. The combination of physical caregiving demands, grief, and uncertainty is genuinely one of the most stressful experiences a person can go through. Seeking support from palliative care social workers, cancer support groups, or a therapist is not a sign of weakness; it reflects the reality of what the disease asks of the people surrounding the patient.
Non-Drug Comfort Measures
Alongside medications, non-pharmacological interventions play a real role in the final stages. Research on comfort care in palliative settings has examined a range of approaches, from massage and music therapy to guided relaxation and aromatherapy, with sessions typically lasting between five and sixty minutes.25PubMed Central. Use of non-pharmacological interventions for comforting patients in palliative care: a scoping review None of these are cures, and the evidence base is modest, but they can reduce anxiety, ease pain perception, and provide moments of human connection when medical interventions have little more to offer.
Simple measures matter too. Keeping the room at a comfortable temperature, playing familiar music quietly, reading aloud, and providing gentle touch or hand-holding are things any family member can do. Even when the patient appears unresponsive, hearing is thought to be one of the last senses to fade. Speaking to someone in their final hours, telling them you love them, giving them permission to let go, is not just for the family’s benefit. There is a reasonable chance the patient can still hear.